List of works - Francisco Javier Gamo

(+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium.

scientific article

Aminoazabenzimidazoles, a novel class of orally active antimalarial agents

scientific article

G6PD variant distribution in sub-Saharan Africa and potential risks of using chloroquine/hydroxychloroquine based treatments for COVID-19

scientific article published on 02 June 2020

Global phenotypic screening for antimalarials

scientific article

Histone methyltransferase inhibitors are orally bioavailable, fast-acting molecules with activity against different species causing malaria in humans

scientific article

In vitro selection predicts malaria parasite resistance to dihydroorotate dehydrogenase inhibitors in a mouse infection model

scientific article published on 01 December 2019

Isoxazolopyrimidine-Based Inhibitors of Dihydroorotate Dehydrogenase with Antimalarial Activity

Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics

scientific article published in January 2018

N-aryl-2-aminobenzimidazoles: novel, efficacious, antimalarial lead compounds

scientific article published on 21 July 2014

Novel Antimalarial Tetrazoles and Amides Active against the Hemoglobin Degradation Pathway in <i>Plasmodium falciparum</i>

scientific article published on 23 February 2021

Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond

scientific article (publication date: July 2016)

Open Source Drug Discovery: Highly Potent Antimalarial Compounds Derived from the Tres Cantos Arylpyrroles

scientific article published on 14 September 2016

Open-source discovery of chemical leads for next-generation chemoprotective antimalarials

scientific article published on 01 December 2018

Quinolone-3-diarylethers: a new class of antimalarial drug.

scientific article published in March 2013

Structure-Guided Lead Optimization of Triazolopyrimidine-Ring Substituents Identifies Potent Plasmodium falciparum Dihydroorotate Dehydrogenase Inhibitors with Clinical Candidate Potential

scientific article

Trisubstituted Pyrimidines as Efficacious and Fast-Acting Antimalarials

scientific article published on 17 June 2016

Validation of the protein kinase PfCLK3 as a multistage cross-species malarial drug target

scientific article

List of works by Francisco Javier Gamo

(+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium.

Aminoazabenzimidazoles, a novel class of orally active antimalarial agents

G6PD variant distribution in sub-Saharan Africa and potential risks of using chloroquine/hydroxychloroquine based treatments for COVID-19

Global phenotypic screening for antimalarials

Histone methyltransferase inhibitors are orally bioavailable, fast-acting molecules with activity against different species causing malaria in humans

In vitro selection predicts malaria parasite resistance to dihydroorotate dehydrogenase inhibitors in a mouse infection model

Isoxazolopyrimidine-Based Inhibitors of Dihydroorotate Dehydrogenase with Antimalarial Activity

Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics

N-aryl-2-aminobenzimidazoles: novel, efficacious, antimalarial lead compounds

Novel Antimalarial Tetrazoles and Amides Active against the Hemoglobin Degradation Pathway in <i>Plasmodium falciparum</i>

Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond

Open Source Drug Discovery: Highly Potent Antimalarial Compounds Derived from the Tres Cantos Arylpyrroles

Open-source discovery of chemical leads for next-generation chemoprotective antimalarials

Quinolone-3-diarylethers: a new class of antimalarial drug.

Structure-Guided Lead Optimization of Triazolopyrimidine-Ring Substituents Identifies Potent Plasmodium falciparum Dihydroorotate Dehydrogenase Inhibitors with Clinical Candidate Potential

Trisubstituted Pyrimidines as Efficacious and Fast-Acting Antimalarials

Validation of the protein kinase PfCLK3 as a multistage cross-species malarial drug target